References
- Health resources—Health spending—OECD Data. Verfügbar unter: https://data.oecd.org/healthres/health-spending.htm. zitiert 10. März 2022.
- Global Health Expenditure Database. 2021. Verfügbar unter: https://apps.who.int/nha/database. . zitiert 27. August 2021.
- IQVIA, The Global Use of Medicine in 2019 and Outlook to 2023. 2019. Verfügbar unter: https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023. zitiert 27. August 2021.
- Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E. Pharmaceutical regulation in 15 European countries review. Health Syst Transit Oktober. 2016;18(5):1–122.
- Paris V, Belloni A. Value in Pharmaceutical Pricing. 11. Juli 2013; Verfügbar unter: https://www.oecd-ilibrary.org/content/paper/5k43jc9v6knx-en. zitiert 27. August 2021.
- Lauenroth VD, Stargardt T. Pharmaceutical pricing in Germany: how is value setermined within the Scope of AMNOG? Value Health. 2017;20(7):927–35.
- Festbeträge für Arzneimittel - Bundesgesundheitsministerium [Internet]. Verfügbar unter: https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/f/festbetraege-fuer-arzneimittel.html. zitiert 11. März 2022.
- BfArM - Arzneimittel-Festbeträge. Verfügbar unter: https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Festbetraege-und-Zuzahlungen/Festbetraege/_node.html;jsessionid=CBD182C36BA610C6EA606B3E4DF62868.intranet252. . zitiert 11. März 2022.
- AMNOG – Nutzenbewertung von Arzneimitteln gemäß § 35a SGB V - Gemeinsamer Bundesausschuss. Verfügbar unter: https://www.g-ba.de/themen/arzneimittel/arzneimittel-richtlinie-anlagen/nutzenbewertung-35a/. zitiert 11. März 2022.
- Pieter Dylst, Arnold G Vulto, Steven Simoens. Reference pricing systems in Europe: characteristics and - GaBI Journal. Verfügbar unter: http://gabi-journal.net/reference-pricing-systems-in-europe-characteristics-and-consequences.html. zitiert 27. August 2021.
- Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:625296.
- Mitkova Z, Vasileva M, Savova A, Manova M, Terezova S, Petrova G. Comparison of cardiovascular medicines prices in four European countries. Front Public Health. 2020;8:433.
- Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 2020;21(5):664–70.
- Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care Februar. 2018;24(2):109–112.
- Yang JJ, Pham AT, Maloney NJ, Aly O, Cheng K. Psoriasis drugs in the medicare population: dermatologists’ spending and prescription patterns. J Dermatolog Treat. 20. Januar 2021;1–4.
- Peter P, Lipska K. The rising cost of diabetes care in the USA. Lancet Diabetes Endocrinol Juni. 2016;4(6):479–480.
- Moye-Holz D, Vogler S. Comparison of prices and affordability of cancer medicines in 16 countries in Europe and Latin America. Appl Health Econ Health Policy. 2021. https://doi.org/10.1007/s40258-021-00670-4.
- Morgan SG, Bathula HS, Moon S. Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ. 2020;368:14627.
- Henschke C, Sundmacher L, Busse R. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation. Health Policy. 2013;109(3):263–269.
- Stargardt T, Schreyögg J. Impact of cross-reference pricing on pharmaceutical prices: manufacturers’ pricing strategies and price regulation. Appl Health Econ Health Policy. 2006;5(4):235–247.
- LAUER-TAXE® Online 4.0, CGM Lauer, Extraction date: 1st of June 2021. Verfügbar unter: https://webapo-info.lauer-fischer.de/LTO40.160101/taxe. zitiert 15. September 2021.
- Danzon PM, Ketcham JD. reference pricing of pharmaceuticals for medicare: evidence from Germany, the Netherlands, and New Zealand. Forum Health Econ & Policy. 2004.https://doi.org/10.2202/1558-9544.1050/html.
- Herr A, Suppliet M. Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany. DICE Discussion Paper; 2012. Report No.: 48. Verfügbar unter: https://www.econstor.eu/handle/10419/57630. zitiert 11. März 2022.
- Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy. 1998;44(1):73–85.
- Anatomical Therapeutic Chemical (ATC) Classification. Verfügbar unter: https://www.who.int/tools/atc-ddd-toolkit/atc-classification. zitiert 6. Juli 2021.
- Top pharmaceutical companies by revenue worldwide 2021. Statista. Verfügbar unter: https://www.statista.com/statistics/281306/major-global-pharmaceutical-companies-based-on-pharma-revenue-2012/. zitiert 10. März 2022.
- The top 20 pharma companies by 2020 revenue | Fierce Pharma. Verfügbar unter: https://www.fiercepharma.com/special-report/top-20-pharma-companies-by-2020-revenue. zitiert 10. März 2022.
- Lauenroth VD, Stargardt T. Pharmaceutical pricing in Germany: how is value determined within the scope of AMNOG? Value Health. 2017;20(7):927–935.
- Trotz hoher Einsparungen weiter steigende Arzneimittelausgabe. www.springer.com. Verfügbar unter: https://www.springer.com/gp/about-springer/media/press-releases/medicine/trotz-hoher-einsparungen-weiter-steigende-arzneimittelausgaben/18375610. zitiert 13. Juni 2022.
- GKV-Spitzenverband. Erfolgsmodell: Seit 30 Jahren sichern Arzneimittel-Festbeträge bezahlbare und hochwertige Versorgung - GKV-Spitzenverband. GKV-Spitzenverband; . Verfügbar unter: https://www.gkv-spitzenverband.de/gkv_spitzenverband/presse/pressemitteilungen_und_statements/pressemitteilung_864192.jsp. zitiert 13. Juni 2022.
- Schlueter M, Chan K, Lasry R, Price M. The cost of cancer—a comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe. PLoS ONE. 2020;15(11):e0241354.
- Vandenberghe D, Albrecht J. The cost of non-communicable disease in the European Union; a future projection. In 2019.
- Cernuschi T, Gilchrist S, Hajizada A, Malhame M, Mariat S, Widmyer G. Price transparency is a step towards sustainable access in middle income countries. BMJ. 2020;368:l5375.
- Suleman F, Low M, Moon S, Morgan SG. New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines. BMJ. 2020;368:l4408.
- Koskinen H, Ahola E, Saastamoinen LK, Mikkola H, Martikainen JE. The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland. Health Econ Rev. 2014;4(1):9.
- Costa E, Santos C. Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs’ reimbursements. Eur J Health Econ. 2022. https://doi.org/10.1007/s10198-022-01440-2.
- Ludwig WD, Mühlbauer B. Arzneiverordnungen 2020 im Überblick. In: Ludwig WD, Mühlbauer B, Seifert R, Herausgeber. Arzneiverordnungs-Report 2021. Berlin, Heidelberg: Springer; 2021. S. 3–35. Verfügbar unter: https://doi.org/10.1007/978-3-662-63825-5_1. zitiert 11. März 2022.